Recently, Immunotherapy, the immune checkpoint inhibitors such as PD-1 or PD-L1, has revolutionized the treatment paradigm for malignant cancer, establishing itself as the novel benchmark for managing locally advanced and metastatic non-small cell lung cancer (NSCLC) patients [2]. Here, CD274 is linked to non-small cell lung carcinoma.